The Landscape of Candidemia During the Coronavirus Disease 2019 (COVID-19) Pandemic
- 18 June 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 74 (5), 802-811
- https://doi.org/10.1093/cid/ciab562
Abstract
The COVID-19 pandemic has resulted in unprecedented healthcare challenges, and COVID-19 has been linked to secondary infections. Candidemia, a fungal healthcare-associated infection, has been described in patients hospitalized with severe COVID-19. However, studies of candidemia and COVID-19 coinfection have been limited in sample size and geographic scope. We assessed differences in patients with candidemia with and without a COVID-19 diagnosis. We conducted a case-level analysis using population-based candidemia surveillance data collected through the Centers for Disease Control and Prevention’s Emerging Infections Program during April–August 2020 to compare characteristics of candidemia patients with and without a positive test for COVID-19 in the 30 days before their Candida culture using chi-square or Fisher’s exact tests. Of the 251 candidemia patients included, 64 (25.5%) were positive for SARS-CoV-2. Liver disease, solid-organ malignancies, and prior surgeries were each >3 times more common in patients without COVID-19 coinfection, whereas intensive care unit–level care, mechanical ventilation, having a central venous catheter, and receipt of corticosteroids and immunosuppressants were each >1.3 times more common in patients with COVID-19. All-cause in-hospital fatality was 2 times higher among those with COVID-19 (62.5%) than without (32.1%). One-quarter of candidemia patients had COVID-19. These patients were less likely to have certain underlying conditions and recent surgery commonly associated with candidemia and more likely to have acute risk factors linked to COVID-19 care, including immunosuppressive medications. Given the high mortality, it is important for clinicians to remain vigilant and take proactive measures to prevent candidemia in patients with COVID-19.Funding Information
- Centers for Disease Control and Prevention (CDC-RFA-CK17-1701)
This publication has 27 references indexed in Scilit:
- The Changing Epidemiology of Candidemia in the United States: Injection Drug Use as an Increasingly Common Risk Factor-Active Surveillance in Selected Sites, United States, 2014-2017Clinical Infectious Diseases, 2020
- Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational studyThe Lancet Respiratory Medicine, 2020
- Population-Based Active Surveillance for Culture-Confirmed Candidemia — Four Sites, United States, 2012–2016Morbidity and Mortality Weekly Report, 2019
- Impact of Infectious Disease Consultation on Clinical Management and Mortality in Patients With CandidemiaClinical Infectious Diseases, 2018
- Estimation of Direct Healthcare Costs of Fungal Diseases in the United StatesClinical Infectious Diseases, 2018
- Candida auris: The recent emergence of a multidrug-resistant fungal pathogenMedical Mycology, 2018
- Invasive candidiasisNature Reviews Disease Primers, 2018
- Epidemiology of Hospitalizations Associated with Invasive Candidiasis, United States, 2002–20121Emerging Infectious Diseases, 2016
- Invasive CandidiasisThe New England Journal of Medicine, 2015
- Excess Costs of Hospital Care Associated With Neonatal CandidemiaThe Pediatric Infectious Disease Journal, 2007